Please use this identifier to cite or link to this item:
|dc.title||Awaiting a new era of cancer immunotherapy|
|dc.identifier.citation||Hong, C.W., Zeng, Q. (2012-08-01). Awaiting a new era of cancer immunotherapy. Cancer Research 72 (15) : 3715-3719. ScholarBank@NUS Repository. https://doi.org/10.1158/0008-5472.CAN-12-0063|
|dc.description.abstract||A major challenge in cancer therapy is the lack of specificity for cancer cells. Antibody-based therapies have better specificity and, thus, improved efficacy over standard chemotherapy regimens. Monoclonal antibodies (mAb) constitute the most rapidly growing class of human therapeutics and are proven agents for recognizing and destroying malignant cells. However, the development of antibody therapies has focused only on targeting extracellular (cell-surface or secreted) proteins rather than intracellular targets (within cells, such as phosphatases and/or kinases and transcription factors), because antibodies are generally believed to be too large to enter cells, resulting in a large untapped source of intracellular therapeutic targets. Recently, we presented evidence that suggests that intracellular proteins with high expression in cancer cells are useful targets for mAb-based or vaccination immunotherapies, thus challenging current understanding. Here, we further discuss the concept and future uses of these immunotherapies against a large pool of intracellular oncoproteins for cancer therapy. This line of research has the potential to vastly expand the field of antibody therapy and usher in a new era of cancer vaccines. ©2012 AACR.|
|dc.contributor.department||INSTITUTE OF MOLECULAR & CELL BIOLOGY|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.